Neurofibroma, Plexiform: all 68 studies
Page 1 of 1. Open to participants first (18), then studies with results posted, then the rest; newest registration first within each.
- Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform NeurofibromasRecruitingNCT07407803Phase 3
- Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1Not yet recruitingNCT07024394Phase 1/2
- PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform NeurofibromasRecruitingNCT06961565Phase 1
- Low-dose Selumetinib for the Treatment of Plexiform Neurofibromas in Chinese ChildrenNot yet recruitingNCT06763315Phase 2
- A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1RecruitingNCT06541847Phase 2
- Neurofibromatosis Type 1 Tumor Early Detection StudyEnrolling by invitationNCT06515860
- A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)RecruitingNCT06507748Not applicable
- Study of Cabozantinib With Selumetinib for Plexiform NeurofibromasRecruitingNCT06502171Phase 1
- A Retrospective Study on Epidemiological Characteristics of Chinese NF1 Patients in Real World (PROMISE)RecruitingNCT06379230
- Real-World Treatment Study of Koselugo (Selumetinib)RecruitingNCT06360406
- Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)RecruitingNCT06222203
- Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1RecruitingNCT06188741Phase 2
- HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform NeurofibromasRecruitingNCT05331105Phase 2
- Developing Biomarkers of Plexiform Tumor Burden in Patients With Neurofibromatosis-Type 1Enrolling by invitationNCT05238909
- Evaluation of Percutaneous Cryotherapy in the Treatment of Plexiform Neurofibromas and Unresectable Neurofibromas in Neurofibromatosis Type 1RecruitingNCT05199376Not applicable
- Individual Patient Compassionate Use of MirdametinibAvailableNCT05028166
- Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)RecruitingNCT02544022
- Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...RecruitingNCT02390752Phase 1
- Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform NeurofibromasActive, not recruitingNCT04924608Phase 3Results posted
- MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform NeurofibromasActive, not recruitingNCT03962543Phase 2Results posted
- Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1(NF1) on Clinical Treatment TrialsCompletedNCT03531814Not applicableResults posted
- Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform NeurofibromasCompletedNCT03231306Phase 2Results posted
- Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic PainCompletedNCT02471339Phase 3Results posted
- Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 MutationsCompletedNCT02124772Phase 1/2Results posted
- Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and AdultsCompletedNCT02101736Phase 2Results posted
- Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform NeurofibromasCompletedNCT01673009Phase 2Results posted
- Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform NeurofibromasTerminatedNCT01402817Phase 2Results posted
- Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1)TerminatedNCT01365468Phase 2Results posted
- Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform NeurofibromasCompletedNCT01275586Early Phase 1Results posted
- Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform NeurofibromasCompletedNCT01140360Phase 1/2Results posted
- A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform NeurofibromasCompletedNCT00634270Phase 2Results posted
- Study of PEG-Intron for Plexiform NeurofibromasCompletedNCT00396019Phase 2Results posted
- AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the SpineTerminatedNCT00326872Phase 2Results posted
- Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform NeurofibromasCompletedNCT00076102Phase 2Results posted
- Fludeoxyglucose F 18 Positron Emission Tomography and Magnetic Resonance Perfusion Imaging in Patients With Neurofibromatosis 1 and Plexiform NeurofibromaTerminatedNCT00060008Not applicableResults posted
- Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform NeurofibromasCompletedNCT00030264Phase 2Results posted
- R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform NeurofibromasCompletedNCT00021541Phase 2Results posted
- Observational Study to Evaluate the Effect and Safety of Selumetinib in Pediatric Patients With NF1-PNsActive, not recruitingNCT06175637
- A Study of Avutometinib for People With Solid Tumor CancersActive, not recruitingNCT06104488Phase 1
- FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform NeurofibromasActive, not recruitingNCT05913037Phase 3
- Selumetinib in Chinese Paediatric With Post-operative NF1-PNs, PhaseⅡ, Double-Blinded, Placebo-Controlled StudyWithdrawnNCT05825365Phase 2
- US Selumetinib RegistryTerminatedNCT05683678
- Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1Active, not recruitingNCT04954001Phase 1/2
- Systematically Assessing Changes in Plexiform Neurofibroma Related Disfigurement From Photographs of Subjects With Neurofibromatosis Type 1 on a Phase 2 Clinical TrialCompletedNCT04879160
- Incidence of Malignant Peripheral Nerve Sheath Tumor (MPNST) Development in Participants With Neurofibromatosis Type 1 (NF1) Receiving and Not Receiving Medical Therapies Directed at Plexiform Neurofibromas (PN)CompletedNCT04774289
- A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)Active, not recruitingNCT04590235Phase 1
- Pediatric Long-Term Follow-up and Rollover StudyActive, not recruitingNCT03975829Phase 4
- Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1Active, not recruitingNCT03820778Not applicable
- Treatment of NF1-related Plexiform Neurofibroma With TrametinibActive, not recruitingNCT03741101Phase 2
- Study of Imatinib in Children With Neurofibromatosis and Airway TumorsWithdrawnNCT03688568Phase 2
- A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male ParticipantsCompletedNCT03649165Phase 1
- Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.Active, not recruitingNCT03363217Phase 2
- Intermittent Dosing Of Selumetinib In Childhood NF1 Associated TumoursCompletedNCT03326388Phase 1/2
- An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1Approved for marketingNCT03259633
- Clinical Sequencing of Cancer and Tissue Repository: OncoGenomicsWithdrawnNCT03027401
- Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach.CompletedNCT02777775
- MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform NeurofibromasActive, not recruitingNCT02407405Phase 2
- Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform NeurofibromasTerminatedNCT02177825Phase 2
- PET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1)CompletedNCT01800032
- Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform NeurofibromasCompletedNCT01412892Phase 2
- AZD6244 Hydrogen Sulfate for Children With Nervous System TumorsActive, not recruitingNCT01362803Phase 1/2
- Natural History Study of Patients With Neurofibromatosis Type IActive, not recruitingNCT00924196
- Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform NeurofibromasCompletedNCT00727233Phase 1
- Phase I Clinical Study of the Safety of Photodynamic Therapy (PDT) Using LS11 in Children With Plexiform NeurofibromasTerminatedNCT00716469Phase 1
- Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug DevelopmentCompletedNCT00340522
- PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform NeurofibromaCompletedNCT00253474Phase 1
- Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform NeurofibromasCompletedNCT00053937Phase 1
- Study of Plexiform Neurofibromas in Neurofibromatosis Type 1CompletedNCT00006435